HOME >> MEDICINE >> NEWS
Media focus on endostatin helped -- not hurt --

that heralded the discovery and development of an agent called recombinant human endostatin (rh-Endo), an angiogenesis inhibitor designed to dry up a tumor's source of blood, starving it. In the article, researchers predicted endostatin might quickly prove to be a cure for cancer. The media blitz that followed was unusual in medical reporting because the drug had not been formally tested in humans.

When M. D. Anderson researchers geared up to run a small Phase I clinical trial of rh-Endo -- one of three centers in the country to conduct such a study -- they were ethically concerned that such "hyperbolic" coverage both in 1998 and at the launch of the clinical trials might draw patients who had little understanding of the purpose of a Phase I clinical trial, but were solely focused on the drug's ability to save their lives. Patients admitted into this beginning phase of testing have no curative treatment options, yet these trials are designed to determine safety and optimal dose, and monitor effectiveness -- it is not intended to prove clinical benefit.

To see if their worries were justified, they asked patients who were referred to the trial from physicians at M. D. Anderson to participate in a survey. Some of these patients were not being cared for at M. D. Anderson, but subsequently contacted the cancer center in the hopes of being seen and referred to the trial.

The seven-member ethics research team analyzed media coverage of the agent from 1997 to 2000 in three newspapers known for medical reporting -- The New York Times, Boston Globe and Chicago Tribune. They found that the majority of coverage was generally positive on the promise of endostatin -- only 25 percent of the articles gave what researchers called a "factual account."

They then surveyed 100 patients referred to the endostatin trial between October 1999 and November 2000. Almost half of survey participants (47 percent) had heard about endostatin from media sources, and 51 pe
'"/>

Contact: Julie Penne or Laura Sussman
jpenne@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
13-Sep-2002


Page: 1 2 3 4

Related medicine news :

1. Media update: GSA underscores hottest meeting topics
2. Media invitation first annual EDCTP Forum
3. Media invitation - European Society of Cardiology Congress 2004
4. Media invitation: The Movement Disorder Societys 7th International Congress
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Review of preliminary observations concludes the Mayo Clinic Natl Conf on Medicine and the Media
7. Media undermine efforts to tackle nicotine addiction
8. Media advisory: Mayo Clinic study finds infliximab safe and beneficial for Crohns disease
9. Media coverage of new drugs is often misleading
10. Media advisory: Mayo Clinic study shows increased incidence of migraines in women
11. American Heart Association Media Advisory: Cholesterol Lowering Margarines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Media focus endostatin helped not hurt

(Date:7/28/2015)... ... ... Morristown Medical Center, part of Atlantic Health System, today announced it was ... the nation, to implant the newly approved CoreValve® Evolut® R System from Medtronic. The ... condition. , The CoreValve® Evolut® R System was approved by the U.S. Food and ...
(Date:7/28/2015)... Francisco, California (PRWEB) , ... July 28, 2015 , ... ... the results from a recent survey (1) examining consumers’ perspectives on digital ... June 17-24, 2015, covered topics such as innovations in digital health, level of trust ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Kinetic Data announced that Schneider Electric has completed its upgrade and expansion ... a global organization with more than 170,000 employees in 134 countries supplying a ...
Breaking Medicine News(10 mins):Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4
(Date:7/28/2015)... 2015  For many medical institutions and universities, commercializing ... inventors can be a constant challenge. Taking an idea ... are rare. A new company in ... Medical Device Investments (MDI) was created to commercialize ... physicians. MDI develops, manufactures and markets the products, with ...
(Date:7/28/2015)... , July 28, 2015   CSL ... for review a Marketing Authorization Application (MAA) for ... coagulation factor IX with recombinant albumin (rIX-FP) for ... people with Hemophilia B. Upon Swissmedic approval, rIX-FP ... treatment option with dosing intervals up to 14 ...
(Date:7/28/2015)... , July 28, 2015 VirtualScopics, Inc. (NASDAQ: ... imaging solutions, today announced that it will report its ... ET market close on Tuesday, August 11, 2015.  ... and Jim Groff , chief financial officer, will ... company,s financial results and provide a business update at ...
Breaking Medicine Technology:Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
Cached News: